Home > Result Summaries: Compounds > ropinirole > Result Summary for 101468/169

Result Summary for 101468/169

Result Summary

Protocol ID:	101468/169
Clinical Study ID:	101468/169
Official Title:	A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment with Ropinirole CR as Adjunctive Therapy in Patients with Parkinson's Disease who are not Optimally Controlled on L-dopa
Phase:	phase 3
Study Indications or Diseases:	Parkinson Disease
Generic Name:	ropinirole
Trade/Product Name:	Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	M Stacy, R Pahwa, N Earl Ropinirole 24-hour prolonged release reduces “off” time and reduces the need for L-dopa when used as adjunctive therapy in patients with advanced Parkinson’s Disease Movement Disorders, November 2006: 21 (Suppl 15) S596/P972 B P Hersh, S A Factor, L Giorgi Ropinirole 24-hour prolonged release improves motor function and activities of daily living as an adjunct to L-dopa in Parkinson’s Disease. Eur J Neurol. September 2006/Suppl 2: 13/S2-P2202 R Pahwa, MA Stacy, SA Factor, KE Lyons, F Stocchi, BP Hersh, LW Elmer, DD Truong, NL Earl, Ropinirole 24 hour prolonged release: Randomised controlled study in advanced Parkinson’s disease. Neurology, 2007. 68: 1108-1115 R Pahwa, F Stocchi, M A Stacy Ropinirole 24-hour prolonged release is effective in sparing L-dopa dose and improving symptoms as adjuctive therapy in Parkinson’s Disease. Eur J Neurol, September 2005/Suppl 2:s2-P2203 R A Hauser, M A Stacy, B P Hersh Ropinirole 24 hour prolonged release reduces off time and improves depression when used as adjunctive therapy in patients with Parkinson’s disease not optimally controlled with L-dopa Movement Disorders S15-21-P8 R Pahwa, M Stacy, E Elmer, S Isaacson Ropinirole 24-hour prolonged release provides efficacy as early as Week 2 when used as adjunctive therapy to L-dopa in patients with advanced Parkinson’s Disease Movement Disorders, November 2006: 21 (Suppl 15) S595/P968. R Pahwa, S Factor, L Elmer Ropinirole 24 hour prolonged release reduces awake time spent “off” in patients with Parkinson’s disease not optimally controlled with L-dopa. Neurology, April 2006. 66 (Suppl 2): A292. P05.135 K Sethi, N Earl, R Hauser Ropinirole 24-hour prolonged release improves disease-specific and global symptoms when used as adjunctive therapy to L-dopa in patients with advanced Parkinson’s Disease. Movement Disorders, November 2006; 21 (Suppl.15) S570/P887 K Ray Chaudhuri, Pablo Martinez-Martin, Katie Rolfe, James Cooper, Carol Rockett, Luigi Giorgi, Bill Ondo. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease . [Eur J Neurol]. 2012;19(1):105-113. F Stocchi, M A Stacy, L Giorgi, N L Earl Safety and tolerability of ropinirole 24-hour prolonged release as adjuctive therapy to L-dopa in patients with Parkinson’s Disease. Eur J Neurol. September 2006/Suppl 2-13/a2P2201 R Pahwa, SA Factor, L Elmer Ropinirole 24 hour prolonged release reduces “off” time in patients with Parkinson’s disease not optimally controlled with L-dopa. Eur J Neurol, September 2006/Suppl2, 13/s2:P2154. Heinz Reichmann, James Cooper, Katie Rolfe, Pablo Martinez-Martin. Sleep Duration and "on" Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release. [Park Dis]. 2011;2011(354760):1-8. M A Stacy, K D Sethi, N L Earl Ropinirole 24-hour prolonged release improves sleep but does not increase daytime sleepiness when used as adjunctive therapy in patients with Parkinson’s Disease not optimally controlled by L-dopa. Movement Disorders, November 2006 S15/9.21:1543-1559 F Stocchi, B Hersh, N Earl, B Scott Safety and tolerability of ropinirole 24-hour prolonged release in patients with early and advanced Parkinson’s Disease. Movement Disorders, November 2006; 21 (Suppl.15) S572/P894.